SCHEMBL3671789

SCHEMBL3671789

CC(=O)[C@H]1C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.69
SHBG P04278 8/20 0.69
SMN1; SMN2 Q16637 7/20 0.69
SERPINA6 P08185 7/20 0.69
CYP3A4 P08684 6/20 0.69
MAPK1 P28482 6/20 0.69
ALDH1A1 P00352 6/20 0.69
TSHR P16473 5/20 0.69
MAPT P10636 5/20 0.69
NR3C1 P04150 4/20 0.69
PGR P06401 3/20 0.69
AR P10275 3/20 0.69
GPBAR1 Q8TDU6 3/20 0.69
SIGMAR1 Q99720 3/20 0.69
PMP22 Q01453 3/20 0.69
NPSR1 Q6W5P4 3/20 0.69
CYP2C9 P11712 2/20 0.69
HIF1A Q16665 2/20 0.69
CYP2C19 P33261 2/20 0.69
MEN1 O00255 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3225890 0.89 LMNA (0.66) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL13753024 0.85 LMNA (0.70) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL4105501 0.85 LMNA (0.70) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL3669271 0.85 LMNA (0.70) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL3672474 0.84 CYP3A4 (0.63) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL3672472 0.84 CYP3A4 (0.63) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL15011284 0.84 CYP3A4 (0.63) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL10438255 0.82 LMNA (0.72) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
Progesterone SCHEMBL23568915 0.81 CYP3A4 (1.00) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
Progesterone SCHEMBL3932110 0.81 CYP3A4 (1.00) LMNASHBGSMN1; SMN2SERPINA6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360673-A1 HAIR COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2017-12-21 US claimed
EP-3236927-A1 HAIR COMPOSITION Unilever PLC (GB) 2017-11-01 EP claimed
WO-2016102177-A1 HAIR COMPOSITION UNILEVER PLC (GB) 2016-06-30 WO claimed
EP-2788088-A1 SKIN ANTI-AGEING COMPOSITION Unilever Plc. (GB) 2014-10-15 EP claimed
US-20140295010-A1 SKIN ANTI-AGEING COMPOSITION CONOPCO, INC. D/B/A UNILEVER (US) 2014-10-02 US claimed
WO-2013083431-A1 SKIN ANTI-AGEING COMPOSITION UNILEVER PLC (GB) 2013-06-13 WO claimed
EP-1627030-A1 NITROGEN REJECTION FROM CONDENSED NATURAL GAS AIR PRODUCTS AND CHEMICALS, INC. (US) 2006-02-22 EP claimed
WO-2004104143-A1 NITROGEN REJECTION FROM CONDENSED NATURAL GAS AIR PRODUCTS AND CHEMICALS, INC. (US) 2004-12-02 WO claimed
WO-2004103376-A2 SKIN TREATMENTS UNILEVER PLC (GB) 2004-12-02 WO claimed
EP-1432399-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2004-06-30 EP claimed
US-20030124159-A1 Enhancing epidermal barrier development in skin UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2003-07-03 US claimed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO claimed
CN-107106628-B Hair composition 荷兰联合利华有限公司 2021-01-12 CN disclosed
US-10456344-B2 Hair composition CONOPCO, INC. (US) 2019-10-29 US disclosed
US-10406091-B2 Skin anti-ageing composition CONOPCO, INC. (US) 2019-09-10 US disclosed
EP-2788088-B1 SKIN ANTI-AGEING COMPOSITION UNILEVER PLC (GB) 2019-06-19 EP disclosed
WO-2004104143-A1 NITROGEN REJECTION FROM CONDENSED NATURAL GAS AIR PRODUCTS AND CHEMICALS, INC. (US) 2004-12-02 WO disclosed
EP-1432399-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2004-06-30 EP disclosed
US-20030124159-A1 Enhancing epidermal barrier development in skin UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2003-07-03 US disclosed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124159-A1 Enhancing epidermal barrier development in skin NR1H2, NR1H3, RXRB LMNA 1129/4885SHBG 1340/4885SMN1; SMN2 4529/4885
US-10456344-B2 Hair composition GLS2, GLS, LHCGR LMNA 1277/4885SHBG 42/4885SMN1; SMN2 4563/4885
US-20170360673-A1 HAIR COMPOSITION GLS2, GLS, CYP17A1 LMNA 1391/4885SHBG 43/4885SMN1; SMN2 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.